Document:

Exhibit 10.8

 

FORM OF

FIRST AMENDMENT TO REGISTRATION RIGHTS
AGREEMENT

 

This First Amendment
to Registration Rights Agreement (this “Amendment”) is dated as of ________________ between Xenetic Biosciences,
Inc., a Nevada corporation (the “Company”), and the purchaser identified on the signature pages hereto (the
“Purchaser”).

 

WHEREAS, the Company
and the Purchaser are parties to that certain Registration Rights Agreement, dated as of July 1, 2015 (as the same is being amended
by this Amendment, and as may be further amended, restated, amended and restated, supplemented or otherwise modified from time
to time, the “Registration Rights Agreement”), pursuant to which the Company granted certain registration rights
with respect to the Company’s common stock, par value $0.01 per share (“Common Stock”), underlying a $3
million Ten Percent (10%) Senior Secured Collateralized Convertible Promissory Note (the “Original Note”) and
a Common Stock Purchase Warrant to purchase up to 10 million shares of common stock of the Company, par value $0.01 per share (the
“Original Warrant”) which were purchased pursuant to that certain Securities Purchase Agreement, dated June
9, 2015 (the “Securities Purchase Agreement”).

 

WHEREAS,
the Company, the Purchaser and AS Kevelt, a subsidiary of the Purchaser, have entered into that certain Asset Purchase
Agreement, dated as of November [__], 2015 (the “Asset Purchase Agreement”), pursuant to which the Company
will purchase certain assets of AS Kevelt and, as part of the transactions contemplated thereby, Purchaser will purchase from
the Company one  or more additional Ten Percent (10%) Senior Secured Collateralized Convertible Promissory Notes (the
“New Notes”) and the Company will issue to the Purchaser  additional Common Stock Purchase Warrants to
purchase up to 11,666,667 shares of common stock of the Company, par value $0.01 per share (the “New
Warrants”).

 

WHEREAS, the parties
have amended certain provisions of the Securities Purchase Agreement (the “SPA Amendment”), to reflect the purchase
of the New Notes and the issuance of the New Warrants and desire to amend certain provisions of the Registration Rights Agreement
to grant the Purchaser registration rights with respect to the shares of Common Stock underlying the New Notes and the New Warrants.

 

NOW, THEREFORE,
IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt
and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows:

 

ARTICLE I.

Amendments and Reaffirmation

 

1.1          Amendments.

 

(a)          The
introductory clause of Section 1 of the Registration Rights Agreement is hereby deleted in its entirety and replaced with the
following:

 

Capitalized terms
used and not otherwise defined herein that are defined in the Securities Purchase Agreement, as amended by the SPA Amendment, shall
have the meanings given such terms in the Securities Purchase Agreement as such terms may be amended by the SPA Amendment.

 

    	1

    	 

    

 

(b)          The definition of Registrable Securities is hereby deleted in its entirety and replaces with the following:

 

“Registrable Securities”
means, as of any date of determination, (a) all of the shares of Common Stock then issued and issuable upon conversion in full
of the Note (assuming on such date the Note is converted in full without regard to any conversion limitations therein), (b) all
shares of Common Stock issued and issuable as interest or principal on the Note assuming all permissible interest and principal
payments are made in shares of Common Stock and the Note is held until maturity, (c) any additional shares of Common Stock issued
and issuable in connection with any anti-dilution provisions in the Note (in each case, without giving effect to any limitations
on conversion set forth in the Note), (d) all of the shares of Common Stock then issued and issuable upon exercise in full of the
Warrant (assuming on such date the Warrant is converted in full without regard to any conversion limitations therein), (e) any
securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with
respect to the foregoing and (f) all other shares of Common Stock issued or issuable to Purchaser or its Affiliates pursuant to
the Asset Purchase Agreement; provided, however, that any such Registrable Securities shall cease to be Registrable
Securities (and the Company shall not be required to maintain the effectiveness of any, or file another, Registration Statement
hereunder with respect thereto) for so long as (a) a Registration Statement with respect to the sale of such Registrable Securities
is declared effective by the Commission under the Securities Act and such Registrable Securities have been disposed of by the Holder
in accordance with such effective Registration Statement, (b) such Registrable Securities have been previously sold in accordance
with Rule 144, or (c) such securities become eligible for resale without volume or manner-of-sale restrictions and without current
public information pursuant to Rule 144 as set forth in a written opinion letter to such effect, addressed, delivered and acceptable
to the Transfer Agent and the affected Holder (assuming that such securities and any securities issuable upon exercise, conversion
or exchange of which, or as a dividend upon which, such securities were issued or are issuable, were at no time held by any Affiliate
of the Company), as reasonably determined by the Company, upon the advice of counsel to the Company.

 

1.2          Reaffirmation.

 

(a)          This Amendment has been duly executed and delivered for the benefit of or on behalf of each of the Company and the Purchaser
and constitutes, in all material respects, a legal, valid and binding obligation of each of the Company and the Purchaser, enforceable
against such party in accordance with its terms except as the enforceability hereof may be limited by bankruptcy, insolvency, reorganization,
moratorium and other laws affecting creditors’ rights and remedies in general.

 

(b)          After giving effect to this Amendment, the representations and warranties contained in the Registration Rights Agreement
and the other Transaction Documents are true and correct in all material respects.

 

(c)          Except as set forth expressly herein, all terms of the Registration Rights Agreement, as amended hereby, and the other Transaction
Documents shall be and remain in full force and effect and shall constitute the legal, valid, binding and enforceable obligations
of the Company and the Purchaser.

 

 

(Signature Pages
Follow)

 

    	2

    	 

    

 

IN WITNESS WHEREOF, the
parties have executed this Amendment as of the date first written above.

 

XENETIC BIOSCIENCES, INC.

 

 

By:____________________________________

      Name: M. Scott Maguire

      Title: Chief Executive Officer 

 

 

 

 

 

 

 

 

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE PAGE FOR PURCHASER FOLLOWS]

 

    	3

    	 

    

 

[SIGNATURE
PAGE OF PURCHASER TO AMENDMENT TO RRA]

 

 

Name of Purchaser: __________________________

 

Signature of Authorized Signatory of Purchaser: __________________________

 

Name of Authorized Signatory: _________________________

 

Title of Authorized Signatory: __________________________

 

 

 

 

 

 

 

 

 

 

 

 

    	4Exhibit 10.9

 

FORM OF

FIRST AMENDMENT TO SECURITY
AGREEMENT

 

This First Amendment
to Security Agreement (this “Amendment”) dated as of ____________, is among Xenetic Biosciences, Inc., a Nevada
corporation (the “Company”), all of the subsidiaries of the Company (such subsidiaries, the “Guarantors”
and together with the Company, the “Debtors”) and the holder(s) of the Company’s Ten Percent (10%) Senior
Secured Collateralized Convertible Promissory Note dated July 1, 2015, in the original principal amount of $3,000,000 (the “Original
Note”) and the Company’s Ten Percent (10%) Senior Secured Collateralized Convertible Promissory Notes (the “New
Notes”) issued in installments as set forth in the Securities Purchase Agreement, dated as of June 9, 2015, as amended (the
“Securities Purchase Agreement”) signatory hereto, its endorsees, transferees and assigns (collectively, the
“Secured Parties”).

 

WHEREAS, the Company
and the Secured Parties are parties to that certain Security Agreement, dated as of July 1, 2015 (as the same is being amended
by this Amendment, and as may be further amended, restated, amended and restated, supplemented or otherwise modified from time
to time, the “Security Agreement”), pursuant to which the Company granted a security interest to the Secured
Parties in substantially all of the assets of Debtors in connection with the Company’s issuance of the Original Note pursuant
to the Securities Purchase Agreement.

 

WHEREAS, the Company
and AS Kevelt, a subsidiary of the Secured Parties, has entered into that certain Asset Purchase Agreement, dated as of November
[__], 2015 (the “Asset Purchase Agreement”), pursuant to which the Company will purchase certain assets of AS
Kevelt and, as part of the transactions contemplated thereby, Secured Party will purchase from the Company the New Notes.

 

WHEREAS, the parties
have amended certain provisions of the Securities Purchase Agreement (the “SPA Amendment”), to reflect the purchase
of the New Notes and desire to amend certain provisions of the Security Agreement to provide that the security interests granted
therein secure the obligations of Debtors under the Original Note and the New Notes.

 

NOW, THEREFORE,
IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt
and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows:

 

ARTICLE I.

Amendments and Reaffirmation

 

1.1          Amendments.

 

(a)          The
introductory clause of Section 1 of the Security Agreement is hereby deleted in its entirety and replaced with the following:

 

Capitalized terms
used and not otherwise defined herein that are defined in the Securities Purchase Agreement, as amended by the SPA Amendment, shall
have the meanings given such terms in the Securities Purchase Agreement as such terms may be amended by the SPA Amendment.

 

    	1

    	 

    

 

(b)          Section 1(a) of the Security Agreement is hereby amended by adding the following to the definition of “Collateral”
as clause (x) and renumbering current clause (x) as clause (xi):

 

“(x) All Purchased Assets (as defined in the Asset Purchase
Agreement); and”

 

(c)          Section 1(e) of the Security Agreement is hereby deleted in its entirety and replaced with the following:

 

“Obligations”
means all of the liabilities and obligations (primary, secondary, direct, contingent, sole, joint or several) due or to become
due, or that are now or may be hereafter contracted or acquired, or owing to, of any Debtor to the Secured Parties, including,
without limitation, all obligations under this Agreement, the Note, the New Notes, the Guarantee, and any other instruments, agreements
or other documents executed and/or delivered in connection herewith or therewith, in each case, whether now or hereafter existing,
voluntary or involuntary, direct or indirect, absolute or contingent, liquidated or unliquidated, whether or not jointly owed with
others, and whether or not from time to time decreased or extinguished and later increased, created or incurred, and all or any
portion of such obligations or liabilities that are paid, to the extent all or any part of such payment is avoided or recovered
directly or indirectly from any of the Secured Parties as a preference, fraudulent transfer or otherwise as such obligations may
be amended, supplemented, converted, extended or modified from time to time. Without limiting the generality of the foregoing,
the term “Obligations” shall include, without limitation: (i) principal of, and interest on the Note and New Notes and
the loans extended pursuant thereto; (ii) any and all other fees, indemnities, costs, obligations and liabilities of the Debtors
from time to time under or in connection with this Agreement, the Note, the New Notes, the Guarantee, and any other instruments,
agreements or other documents executed and/or delivered in connection herewith or therewith; and (iii) all amounts (including but
not limited to post-petition interest) in respect of the foregoing that would be payable but for the fact that the obligations
to pay such amounts are unenforceable or not allowable due to the existence of a bankruptcy, reorganization or similar proceeding
involving any Debtor.

 

1.2          Reaffirmation.

 

(a)          This Amendment has been duly executed and delivered for the benefit of or on behalf of each of the Company and the Secured
Parties and constitutes, in all material respects, a legal, valid and binding obligation of each of the Company and the Secured
Parties, enforceable against such party in accordance with its terms except as the enforceability hereof may be limited by bankruptcy,
insolvency, reorganization, moratorium and other laws affecting creditors’ rights and remedies in general.

 

(b)          After giving effect to this Amendment, the representations and warranties contained in the Security Agreement and the other
Transaction Documents are true and correct in all material respects.

 

(c)          Except as set forth expressly herein, all terms of the Security Agreement, as amended hereby, and the other Transaction
Documents shall be and remain in full force and effect and shall constitute the legal, valid, binding and enforceable obligations
of the Company and the Secured Parties.

 

 

(Signature Pages
Follow)

 

    	2

    	 

    

 

IN WITNESS WHEREOF, the
parties hereto have caused this Amendment to be duly executed on the day and year first above written.

 

	
        XENETIC
        BIOSCIENCES, INC.

         

	
        By:__________________________________________

        Name: M. Scott Maguire

        Title:

	 
	
        Xenetic
        Biosciences (UK) Limited

         

	
        By:__________________________________________

        Name: M. Scott Maguire

        Title:

         

Lipoxen
Technologies Limited

 

By:__________________________________________

Name: M. Scott Maguire

Title:

 

Xenetic
Bioscience, Incorporated

 

By:__________________________________________

Name: M. Scott Maguire

Title:

 

SymbioTec
GmbH

 

By:__________________________________________

Name: M. Scott Maguire

Title:

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE PAGE FOR THE SECURED PARTIES
FOLLOWS]

 

    	3

    	 

    

[SIGNATURE PAGE OF SECURED PARTIES]

 

Name of Investing Entity: __________________________

 

Signature of Authorized Signatory of Investing
entity: _________________________

 

Name of Authorized Signatory: _________________________

 

Title of Authorized Signatory: __________________________

 

 

 

 

OPKO Pharmaceuticals, LLC

 

By: 
____________________________

 

Name: __________________________

 

Title: 
___________________________

 

 

    	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}]]